IACS-010759 hydrochloride
Based on 28 publication(s) in Google Scholar
IACS-010759 hydrochlorideis an orally active, potent mitochondrial complex I of oxidative phosphorylation (OXPHOS) inhibitor. IACS-010759 hydrochlorideinhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on OXPHOS. IACS-010759 hydrochloride has the potential for relapsed/refractory AML and solid tumors research.
For research use only. We do not sell to patients.
- Purity: 99.66%
- CAS No.: 1807523-99-4
- Formula: C25H26ClF3N6O4S
- Molecular Weight:599.02
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Metabolism/Protease Compound Library
HY-L012
-
Stem Cell Signaling Compound Library
HY-L017
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Reprogramming Compound Library
HY-L039
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Mitochondria-Targeted Compound Library
HY-L089
-
Glucose Metabolism Compound Library
HY-L092
-
Cuproptosis Compound Library
HY-L133
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) IACS-010759 hydrochloride
More- Nat Commun. 2023 Jul 14;14(1):4221. [Abstract]
- J Adv Res. 2025 Mar 17:S2090-1232(25)00186-9. [Abstract]
- Cell Discov. 2022 Oct 6;8(1):102. [Abstract]
- Adv Sci (Weinh). 2025 Nov 9:e07524. [Abstract]
- Adv Sci (Weinh). 2024 Jun 10:e2401396. [Abstract]
- Cell Rep Med. 2022 Nov 15;3(11):100802. [Abstract]
- Cell Death Dis. 2025 Apr 5;16(1):254. [Abstract]
- Cancer Lett. 2025 Feb 1:217512. [Abstract]
- Cell Death Discov. 2026 Jan 19;12(1):86. [Abstract]
- NPJ Precis Oncol. 2025 Nov 21;9(1):373. [Abstract]
- Blood Adv. 2025 Jul 16:bloodadvances.2024015496. [Abstract]
- JCI Insight. 2025 Nov 24;10(22):e187448. [Abstract]
- JCI Insight. 2025 Jul 22;10(14):e189858. [Abstract]
- Cancer Metab. 2025 Mar 31;13(1):16. [Abstract]
- Commun Biol. 2026 May 23. [Abstract]
- Commun Biol. 2023 Mar 10;6(1):255. [Abstract]
- Sci Rep. 2025 Nov 28. [Abstract]
- J Pharmacol Exp Ther. 2025 Jul 15;392(9):103661. [Abstract]
- Carcinogenesis. 2025 Jan 24:bgaf002. [Abstract]
- Biochem Biophys Res Commun. 2023 Sep 3:671:46-57. [Abstract]
- Biochem Biophys Res Commun. 2021 May 7:552:23-29. [Abstract]
- Mutat Res. 2024 Jul 23:829:111875. [Abstract]
- Res Sq. 2026 Jun 15.
- bioRxiv. 2025 Oct 3.
- bioRxiv. 2025 Sep 11:2025.09.10.675369. [Abstract]
- University of Cambridge. 2025.
- bioRxiv. 2024 Mar 21.
- bioRxiv. 2023 Dec 20.
Customer Validation & Images
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
Biological Activity
OXPHOS[1]
IACS-010759 hydrochloride (10, 30, 100?nM; for 4 or 5 days) reduces viability and induces apoptosis in primary AML[1].
?
IACS-010759 hydrochloride (0.001, 0.01, 0.1, 1, 10, 100, 1000 nM; 72 hurs) robustly inhibits both OCR and galactose-dependent H460 cell viability and has nearly identical IC50 values of 1.4?nM[1].
?
IACS-010759 hydrochlorideis similarly active in mouse (average IC50?=?5.6?nM), rat (IC50?=?12.2?nM), and cynomolgus monkey (IC50?=?8.7?nM) cell lines[1].
?
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
? IACS-010759 HCl (10?mg/kg; orally; QD (daily) or QD×5 (5 d on/2 d off); for 35 d) increases median survival from 28 d to longer than 60 d, whereas less-frequent dosing schedules (Q2D or Q3D) enhances survival to a lesser extent[1].
? IACS-010759 hydrochloride (0.3?mg/kg for iv; 1?mg/kg for oral) has low plasma clearance with a high volume of distribution, resulting in a prolonged terminal half-life (>24?h)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1807523-99-4
-
Appearance Solid
-
Molecular Weight 599.02
-
Formula C25H26ClF3N6O4S
-
Color White to off-white
-
SMILES
FC(F)(F)OC1=CC=C(C2=NOC(C3=NN(CC4=CC(N5CCC(S(=O)(C)=O)CC5)=CC=C4)C(C)=N3)=N2)C=C1.Cl
-
Synonyms
IACS-10759 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (28)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers. [Abstract]2023 Jul 14;14(1):4221. PMID: 37452026
IACS-010759 hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Jul 14;14(1):4221. [Abstract]
Response of HBCx-124 to different doses of IACS-010759 (10-75 mg/kg; 5 days per week) and to Metformin P values were calculated with the Mann-Whitney test (two-tailed).
IACS-010759 hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Jul 14;14(1):4221. [Abstract]
Effect of IACS-010759 (0.01 nM-100 μM; 72 h) on in vitro models of ER+ breast cancer sensitive and resistant cells. Relative viability of MCF7 WT/LTED/ PalboR and of T47D WT/LTED derivatives cells.
IACS-010759 hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Jul 14;14(1):4221. [Abstract]
MCF7-LTED and PalboR cells were treated with 1 μM IACS for 72 h and ROS levels were measured using CellROX and DCFDA staining.
-
J Adv Res
Mitochondrial fatty acid oxidation as the target for blocking therapy-resistance and inhibiting tumor recurrence: The proof-of-principle model demonstrated for ovarian cancer cells. [Abstract]2025 Mar 17:S2090-1232(25)00186-9. PMID: 40107354 -
Cell Discov
Lineage-coupled clonal capture identifies clonal evolution mechanisms and vulnerabilities of BRAFV600E inhibition resistance in melanoma. [Abstract]2022 Oct 6;8(1):102. PMID: 36202798 -
Adv Sci (Weinh)
Amphiregulin and Epiregulin Confer Radioresistance in Esophageal Squamous Cell Carcinoma Through Oxidative Phosphorylation. [Abstract]2025 Nov 9:e07524. PMID: 41208199
IACS-010759 hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 9:e07524. [Abstract]
IACS-010759 (7.5 mg/kg; p.o. every other day) enhances irradiation efficacy for ESCC xenograft tumors.
-
Adv Sci (Weinh)
Enzalutamide Sensitizes Castration-Resistant Prostate Cancer to Copper-Mediated Cell Death. [Abstract]2024 Jun 10:e2401396. PMID: 38859590
IACS-010759 hydrochloride purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jun 10:e2401396. [Abstract]
Cell viability was measured for 22Rv1 and C4-2B cells after treatment with IACS-010759 (0.01-1000 nM) in the presence or absence of Enzalutamide for 5 days.
-
Cell Rep Med
Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer. [Abstract]2022 Nov 15;3(11):100802. PMID: 36334593 -
Cell Death Dis
Inhibition of mitochondrial complex I induces mitochondrial ferroptosis by regulating CoQH2 levels in cancer. [Abstract]2025 Apr 5;16(1):254. PMID: 40185704 -
Cancer Lett
Acidosis overrides molecular heterogeneity to shape therapeutically targetable metabolic phenotypes in colon cancers. [Abstract]2025 Feb 1:217512. PMID: 39900217 -
Cell Death Discov
Targeting metabolic vulnerabilities: REV-ERB agonist SR9009 potentiates sorafenib efficacy in liver cancer. [Abstract]2026 Jan 19;12(1):86. PMID: 41554703 -
NPJ Precis Oncol
Integrative profiling strategies to guide personalized therapy in mantle cell lymphoma: a pilot study. [Abstract]2025 Nov 21;9(1):373. PMID: 41272086 -
Blood Adv
Targeting bone marrow mesenchymal stromal cells-derived IL-6 to overcome acute myeloid leukemia chemoresistance. [Abstract]2025 Jul 16:bloodadvances.2024015496. PMID: 40668612 -
JCI Insight
Mitochondrial metabolic rewiring sensitizes mTORC1 inhibitor persister cells to cuproptosis. [Abstract]2025 Nov 24;10(22):e187448. PMID: 41277553 -
JCI Insight
Metabolic pathways within cTfh subsets and glucose-dependent activation of cTfh17 in SLE and healthy individuals. [Abstract]2025 Jul 22;10(14):e189858. PMID: 40693461 -
Cancer Metab
Unveiling the powerhouse: ASCL1-driven small cell lung cancer is characterized by higher numbers of mitochondria and enhanced oxidative phosphorylation. [Abstract]2025 Mar 31;13(1):16. PMID: 40165271 -
Commun Biol
FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach. [Abstract]2026 May 23. PMID: 42177363 -
Commun Biol
Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling. [Abstract]2023 Mar 10;6(1):255. PMID: 36899051 -
Sci Rep
Targeting tumor metabolic flexibility enhances radiotherapeutic efficacy via mitochondrial complex I Inhibition in an intracranial S180 sarcoma mouse model. [Abstract]2025 Nov 28. PMID: 41310084 -
J Pharmacol Exp Ther
Phenotypic pharmacology of novel Complex I inhibitors eliciting tissue repair concurrent to control of inflammation. [Abstract]2025 Jul 15;392(9):103661. PMID: 40782522 -
Carcinogenesis
SMARCA4/BRG1 deficiency induces a targetable dependence on oxidative phosphorylation in clear cell renal cell carcinoma. [Abstract]2025 Jan 24:bgaf002. PMID: 39851260 -
Biochem Biophys Res Commun
Lactic acidosis switches cancer cells from dependence on glycolysis to OXPHOS and renders them highly sensitive to OXPHOS inhibitors. [Abstract]2023 Sep 3:671:46-57. PMID: 37295355 -
Biochem Biophys Res Commun
SWATH-MS proteomics of PANC-1 and MIA PaCa-2 pancreatic cancer cells allows identification of drug targets alternative to MEK and PI3K inhibition. [Abstract]2021 May 7:552:23-29. PMID: 33740661 -
Mutat Res
Saikosaponin-d mediates FOXG1 to reverse docetaxel resistance in prostate cancer through oxidative phosphorylation. [Abstract]2024 Jul 23:829:111875. PMID: 39098234 -
-
-
bioRxiv
2025 Sep 11:2025.09.10.675369. PMID: 40964275 -
-
-
Solvent & Solubility
DMSO : 60 mg/mL (100.16 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6694 mL | 8.3470 mL | 16.6939 mL | 41.7348 mL |
| 5 mM | 0.3339 mL | 1.6694 mL | 3.3388 mL | 8.3470 mL | |
| 10 mM | 0.1669 mL | 0.8347 mL | 1.6694 mL | 4.1735 mL | |
| 15 mM | 0.1113 mL | 0.5565 mL | 1.1129 mL | 2.7823 mL | |
| 20 mM | 0.0835 mL | 0.4173 mL | 0.8347 mL | 2.0867 mL | |
| 25 mM | 0.0668 mL | 0.3339 mL | 0.6678 mL | 1.6694 mL | |
| 30 mM | 0.0556 mL | 0.2782 mL | 0.5565 mL | 1.3912 mL | |
| 40 mM | 0.0417 mL | 0.2087 mL | 0.4173 mL | 1.0434 mL | |
| 50 mM | 0.0334 mL | 0.1669 mL | 0.3339 mL | 0.8347 mL | |
| 60 mM | 0.0278 mL | 0.1391 mL | 0.2782 mL | 0.6956 mL | |
| 80 mM | 0.0209 mL | 0.1043 mL | 0.2087 mL | 0.5217 mL | |
| 100 mM | 0.0167 mL | 0.0835 mL | 0.1669 mL | 0.4173 mL |
IACS-010759 hydrochloride Related Classifications
HY-112037A Related Classifications
Powered by Bioz